Portfolio Companies News
May 6, 2021Targovax ASA: First quarter 2021 re...
Oslo, Norway, 6 May 2021 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its first quarter 2021 results. An online presentation by Targovax’s management to investors, analysts and the press ... read more
May 5, 2021Oncopeptides completes patient enro...
STOCKHOLM — May 5, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has completed patient enrollment in the phase 2 PORT study. ... read more
May 5, 2021Interim report January - March 2021
Gothenburg, May 5, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2021. Important events during the first quarter In February, Vicore completed a directed share issue raising 336 MSEK. The share issue was approved at an Extraordinary General Meeting ... read more
May 4, 2021The Norwegian Directorate of Health...
04 MAY 2021 The Norwegian Directorate of Health has procured Doctrin’s platform for triage for the national entrance for Norway’s residents when seeking healthcare, helsnorge.no. The Norwegian Directorate of Health, together with the Directorate for e-Health and the Norwegian Health ... read more
May 4, 2021Pulmonx Reports First Quarter 2021 ...
May 4, 2021 PDF Version REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the first quarter ended March 31, 202... read more
May 03, 2021Q1 2021 General Market Overview
Since the start in 1996, HealthCap funds have invested in 119 portfolio companies.
46 of the portfolio companies have been taken public on nine different markets.
27 of the portfolio companies pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.